Clinical Trial Update: Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating cemiplimab plus gemcitabine for metastatic pancreatic ductal adenocarcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemzar (gemcitabine)
• Libtayo (cemiplimab)

Snippet

Sponsor: University of California, San Diego | Conditions: Pancreatic Ductal Adenocarcinoma (mPDAC) | Phase 2 | Status: RECRUITING